Items

• Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. (2025-08)

  A. Bar Or, M. Dufek, H. Budincevic, J. Drulovic, M. Habek, L. H Huan, M. SVeber, P. Thomas, FENopta study group S. Grgić, FENopta S. Kidemet Piskac, Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study., THE LANCET NEUROLOGY, Vol. 24, No. 8, pp. 656 - 666, Aug, 2025